home / stock / ymab / ymab news

YMAB News and Press, Y-mAbs Therapeutics Inc.

Stock Information
Company Name: Y-mAbs Therapeutics Inc.
Stock Symbol: YMAB
Market: NASDAQ
Menu
YMAB YMAB Quote YMAB Short YMAB News YMAB Articles YMAB Message Board
Get YMAB Alerts

News, Short Squeeze, Breakout and More Instantly...
YMAB - ES, SFWL and MOBQ among mid-day movers

2023-05-09 13:22:40 ET Gainers: TScan Therapeutics ( TCRX ) +124% . Shengfeng Development Limited ( SFWL ) +102% . Mobiquity Technologies ( MOBQ ) +68% . ClearOne ( CLRO ) +62% . U.S. GoldMining ( USGOW ) +57% . Novavax ( N...
YMAB - TScan, Ensysce top healthcare gainers; Enanta, Lexaria among losers

2023-05-09 10:00:33 ET Gainers: TScan Therapeutics ( TCRX ) +151% . Ensysce Biosciences ( ENSC ) +60% . Novavax ( NVAX ) +36% . Y-mAbs Therapeutics ( YMAB ) +30% . Longeveron ( LGVN ) +26% . Losers: Enanta Pharmaceuti...

YMAB - ANTRA, ENTA and YMAB are among after hour movers

2023-05-08 18:03:40 ET Gainers: Oportun Financial  ( OPRT ) +23% . EverQuote ( EVER ) +22% . Tactile Systems Technology ( TCMD ) +17% . Rover Group ( ROVR ) +14% . Y-mAbs Therapeutics ( YMAB ) +13% . Losers: Enanta P...

YMAB - Y-mAbs Therapeutics GAAP EPS of -$0.15 beats by $0.17, revenue of $20.25M beats by $4.7M

2023-05-08 16:03:02 ET Y-mAbs Therapeutics press release ( NASDAQ: YMAB ): Q1 GAAP EPS of -$0.15 beats by $0.17 . Revenue of $20.25M (+93.0% Y/Y) beats by $4.7M . Financial Guidance We are updating our full-year 2023 financial guidance, which now reflec...
YMAB - Y-mAbs Reports First Quarter 2023 Financial Results and Recent Corporate Developments and Updates 2023 Financial Guidance

Q1 2023 DANYELZA® record net product revenues of $20.3 million, driving YoY growth of 93% and a 24% sequential increase compared to Q4 2022 Management updates 2023 financial guidance, now anticipating higher DANYELZA net revenues of $80-85 million and lower cash burn of $40-50 millio...

YMAB - Y-mAbs to Announce First Quarter 2023 Financial and Operating Results on May 8, 2023

NEW YORK, April 28, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter ended March 31, 2023, on Monday, May 8, 2023, after the close of the U.S. financi...

YMAB - Y-mAbs Announces Presentation of Naxitamab data at AACR

NEW YORK, April 18, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatme...
YMAB - Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial of GD2-SADA

NEW YORK, April 05, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatme...

YMAB - Y-mAbs Therapeutics, Inc. (YMAB) Q4 2022 Earnings Call Transcript

2023-03-31 11:08:09 ET Y-mAbs Therapeutics, Inc. (YMAB) Q4 2022 Earnings Conference Call March 31, 2023 9:00 AM ET Company Participants Thomas Gad - Founder, Interim CEO & President Sue Smith - SVP & Chief Commercial Officer Bo Kruse - EVP, Secretary, Tre...

YMAB - Y-mAbs, G Medical top healthcare gainers; Pyxis, AnPac among losers

2023-03-31 10:05:49 ET Gainers: Y-mAbs Therapeutics ( YMAB ) +43% . G Medical Innovations ( GMVD ) +41% . Palisade Bio ( PALI ) +20% . Inozyme Pharma ( INZY ) +17% . Paratek Pharmaceuticals ( PRTK ) +17% . Losers: Pyxis...
Next 10